We know from other studies that Evusheld protects people from getting severe COVID-19 infections for 6 months to 12 months. However, we do not know how long this protection lasts in people who are immunocompromised and how well it works against emerging COVID-19 variants. This is one of the questions we aim to answer as part of this study. Because we cannot guarantee how long the participant will be protected for, all participants should continue to follow the COVID-19 government guidelines for immunocompromised patients, for example, on isolation and shielding.
Participants may benefit from having an additional COVID-19 vaccine booster although the effect of the vaccine following Evusheld is unknown.
Taking part in this study will mean that participants are contributing to research that may benefit many people who are immunocompromised during the COVID-19 pandemic. We may also find out more about how mono-clonal antibodies and the immune system works which may improve research in the future.